There are multiple options now for slowing the progression of chronic kidney disease. In part 5 of our special series, host Dr. Neil Skolnik takes a case-based approach to explore treatment options for CKD.
This special episode is sponsored with support from Bayer.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Holly Kramer, MD, MPH, Professor of Public Health Sciences and Medicine in the Division of Nephrology and Hypertension at Loyola University in Chicago, Illinois
Selected References:
Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association’s Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 doi.org/10.2337/dc26-S011
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 doi.org/10.1056/NEJMoa2025845
Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 doi.org/10.1056/NEJMoa2024816
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121 doi.org/10.1056/NEJMoa2403347
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care 2023;46(9):1574–1586 doi.org/10.2337/dci23-0030
The Kidney Failure Risk Equation – kidneyfailurerisk.com
Leave a Reply